Autologous Stem Cell Therapy in Patients With Multiple System Atrophy
Key facts
- Where
- Warsaw, PolandSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 35 and 65 years old?
Source: NCT07465198, who can take part
Where in Poland
- Biocells MedicalWarsaw, PolandContact: Miron Danielevich, PhDNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Biocells Medical
- Trial code
- NCT07465198
- Record updated
- 11 March 2026
- Original description
This study investigates the safety and efficacy of autologous stem cell therapy in patients with Multiple System Atrophy (MSA), a rare and progressive neurodegenerative disorder characterized by autonomic failure, parkinsonism, and cerebellar ataxia. The trial will evaluate functional outcomes, motor performance, and quality of life compared to placebo/controlled group.Read full original descriptionShow less
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Autologous Stem Cell Therapy in Patients With Multiple System Atrophy
This study investigates the safety and efficacy of autologous stem cell therapy in patients with Multiple System Atrophy (MSA), a rare and progressive neurodegenerative disorder characterized by autonomic failure, parkinsonism, and cerebellar ataxia. The trial will evaluate functional outcomes, motor performance, and quality of life compared to placebo/controlled group.
Inclusion: Multiple System Atrophy (MSA-P or MSA-C); Age range of 35 to 65 years.
Exclusion: Prior stem cell therapy; Other major neurological disorders; Severe cardiac/renal/hepatic impairment.